Xencor Inc 8-K

What Happened Xencor Inc. (XNCR) filed an 8-K on March 9, 2026 announcing it received notice that Genentech, Inc. elected to terminate the Amended and Restated Collaboration and License Agreement with Genentech and F. Hoffmann‑La Roche Ltd. The filing states the termination is for convenience and that the effective date of termination is September 4, 2026. The sole active collaboration product under the agreement was efbalropendekin alfa, an engineered cytokine‑Fc fusion protein.

Key Details

• Filing: Form 8‑K filed March 9, 2026 (Item 1.02: Termination of a Material Definitive Agreement).
• Termination election: Genentech elected to terminate the Agreement in its entirety for convenience.
• Effective date: Termination effective September 4, 2026 (filing also references a notice effective as of June 1, 2024).
• Program status: Roche removed efbalropendekin alfa from its development pipeline in January 2025; Xencor had opted out of co‑development and ceased cost‑sharing in the first half of 2024, after which Genentech assumed sole responsibility for clinical, regulatory and commercial activities for certain collaboration products.

Why It Matters The filing documents the formal end of a material collaboration between Xencor and Genentech/Roche that centered on efbalropendekin alfa. Because efbalropendekin was the sole active collaboration product and Xencor had already opted out of co‑development, investors should note this confirms the administrative wind‑down of that partnership. Shareholders may want to watch Xencor’s subsequent filings and earnings disclosures for any discussion of financial impacts (milestones, revenue, or expense changes) and updates on the company’s remaining pipeline and development strategy.